Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 24, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

Real-World Experience With Single Ultra-Low Dose Rituximab for Remission Induction in Pemphigus.

Yu-Chen Jeng1, Wei-Ting Liu1, Chao-Kai Hsu1,2,3

  • 1Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

The Journal of Dermatology
|May 23, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DDR1 Modulates Cytoskeletal Remodeling and Podosome Formation in Renal Fibroblasts.

International journal of molecular sciences·2026
Same author

Correction: Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity in Adults in Taiwan: A Cross-sectional Survey.

Dermatology and therapy·2026
Same author

Dermatopathology in 4D: in situ spatial transcriptomics maps the cellular and molecular architecture of skin.

The British journal of dermatology·2026
Same author

Comment on 'Zinc deficiency in bullous pemphigoid: predisposing factors, skin fragility and renal function impact': reply from authors.

The British journal of dermatology·2026
Same author

Risk of skin cancer from hydrochlorothiazide and other diuretics across races: A global cohort study.

Environmental toxicology and pharmacology·2026
Same author

Large cellulitis-like erythematous plaques with overlying nodules on bilateral shins.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Ultra-low dose rituximab (ULRTX) effectively induces remission in pemphigus patients, significantly reducing steroid use and adverse events. This single-dose approach offers a cost-effective and safer alternative to standard-dose rituximab (SDRTX).

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Standard-dose rituximab (SDRTX) is effective for pemphigus but has limitations in cost-effectiveness and safety.
  • Optimizing RTX treatment for pemphigus is crucial for improving patient outcomes and reducing healthcare burdens.

Purpose of the Study:

  • To evaluate the efficacy and safety of a single ultra-low dose rituximab infusion (ULRTX) for inducing remission in pemphigus patients.
  • To assess the potential for corticosteroid sparing and B-cell depletion with ULRTX therapy.
  • To compare the safety profile of ULRTX with standard-dose RTX.

Main Methods:

  • Retrospective evaluation of 12 pemphigus patients treated with a single 100 or 200 mg ULRTX infusion.
  • Assessment of clinical remission (complete remission on minimal therapy [CRMT] and complete remission off therapy [CROT]) and Pemphigus Disease Area Index (PDAI) scores.

Related Experiment Videos

Last Updated: May 24, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

  • Monitoring of corticosteroid dosage, serum anti-desmoglein titers, and peripheral B-cell counts.

    • Main Results:

    • 75% of patients achieved CRMT, with 41.7% achieving CROT.
    • Significant corticosteroid sparing was observed, with 90% of evaluable patients tapering prednisolone to ≤5 mg/day within 6 months.
    • ULRTX demonstrated effective B-cell depletion and a favorable safety profile with significantly fewer adverse events compared to SDRTX (0% vs. 37.5%).

    Conclusions:

    • Single-dose ULRTX is a cost-efficient and biologically effective induction strategy for pemphigus.
    • ULRTX supports a personalized, immunologically guided, on-demand treatment approach.
    • Further research into ULRTX may lead to optimized pemphigus treatment protocols.